Reply to Blot et al. and to Inoue et al.
journal contributionposted on 2022-03-09, 17:02 authored by Oliver McElvaney, Natalie McEvoy, Noel G McElvaneyNoel G McElvaney, Gerard CurleyGerard Curley
We thank Blot and colleagues for their interest in our article and for raising an important question regarding the suitability of IL-6 as a therapeutic target in coronavirus disease (COVID-19).
In their correspondence, Blot and colleagues provide data on IL-6 levels measured in patients with a diagnosis of COVID-19 versus non–COVID-19 pneumonia. Although we believe the data presented by Blot and colleagues are valid, we suggest that the IL-6 levels depicted are, by virtue of sample timing, processing methodology, and patient severity of disease, not comparable to ours and should be interpreted in context.
CommentsThe original article is available at https://www.atsjournals.org/
Published CitationMcElvaney OJ, McEvoy NL, McElvaney NG, Curley GF. Reply to Blot et al. and to Inoue et al. Am J Respir Crit Care Med. 2021;203(1):141-142
Publication Date21 September 2020
- Anaesthetics and Critical Care
- Beaumont Hospital
PublisherAmerican Thoracic Society
- Published Version (Version of Record)
COVID-19CoronavirusSARS-CoV-2PandemicsICUIntensive CareIL-6severitynon–COVID-19 pneumoniacorrespondencecommunity-acquired pneumonia(CAP) groupStreptococcus pneumoniaeRT-PCRhospital admission,disease severityMechanical ventilationinvasive ventilationhyperinflammatory phasebiphasic illnessstudy protocol